In PD-1/PD-L1 immune checkpoint inhibitor cancer treatment, IFN-γ is a prognostic marker. The production of IFN-γ is associated with an improved response to immune checkpoint blockade (ICB ...
The way PD-L1 was expressed differed between different cell types and changed over time. Importantly, certain cytokines like IL-6, IFN-γ, and IL-4 were found to increase PD-L1 expression ...
Hosted on MSN2mon
Study reveals immune-modulatory mechanism of lurbinectedin in small-cell lung cancerMore information: Subhamoy Chakraborty et al, Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer, Cell Reports Medicine (2024). DOI ...
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback